PMID- 36544627 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221223 IS - 2305-5839 (Print) IS - 2305-5847 (Electronic) IS - 2305-5839 (Linking) VI - 10 IP - 22 DP - 2022 Nov TI - Development of a normal tissue complication probability (NTCP) model using an artificial neural network for radiation-induced necrosis after carbon ion re-irradiation in locally recurrent nasopharyngeal carcinoma. PG - 1194 LID - 10.21037/atm-20-7805 [doi] LID - 1194 AB - BACKGROUND: The aim of the present study was to build a normal tissue complication probability (NTCP) model using an artificial neural network (ANN) for radiation-induced necrosis after carbon ion re-irradiation in locally recurrent nasopharyngeal carcinoma (rNPC), and to determine the predictive parameters applied to the model. METHODS: A total of 150 patients with rNPC treated at Shanghai Proton and Heavy Ion Center during 2015-2019 were selected to determine the dominant factors causing mucosal necrosis after carbon therapy. An ANN was built to study both dose-volume histogram (DVH) and clinical factors. Simple oversampling and data normalization were used in the training process. Ten-fold cross validation was conducted to prevent overfitting. RESULTS: Of the DVH factors, the prediction accuracy ranged from 58.3-65.2%, whereas planning target volume (PTV) receiving dose more than 25 GyE (PTV.V25) yielded the best prediction accuracy. Of the clinical factors, baseline necrosis, sex, and biologically equivalent dose (BED) of initial treatment could increase the accuracy of PTV.V25 by 0.5%, 0.5%, and 1.5%, respectively. CONCLUSIONS: An ANN was built to predict radiation-induced necrosis after re-irradiation in rNPC. The best accuracy and area under receiver-operating characteristic (ROC) curve (AUC) were 66.7% and 0.689. The most predictive dosimetric and clinical parameters were PTV.V25 and BED of initial treatment. CI - 2022 Annals of Translational Medicine. All rights reserved. FAU - Wang, Tian AU - Wang T AD - Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China. AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. FAU - Hu, Jiyi AU - Hu J AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China. FAU - Huang, Qingting AU - Huang Q AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China. FAU - Wang, Weiwei AU - Wang W AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China. FAU - Zhang, Xiyu AU - Zhang X AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China. FAU - Zhang, Liwen AU - Zhang L AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China. FAU - Wu, Xiaodong AU - Wu X AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China. FAU - Kong, Lin AU - Kong L AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Hospital, Shanghai, China. FAU - Lu, Jiade Jay AU - Lu JJ AD - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China. AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. AD - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China. LA - eng PT - Journal Article PL - China TA - Ann Transl Med JT - Annals of translational medicine JID - 101617978 PMC - PMC9761129 OTO - NOTNLM OT - Normal tissue complication probability (NTCP) OT - artificial neural network (ANN) OT - locally recurrent nasopharyngeal carcinoma (locally rNPC) OT - recurrent nasopharyngeal carcinoma (rNPC) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-20-7805/coif). The authors have no conflicts of interest to declare. EDAT- 2022/12/23 06:00 MHDA- 2022/12/23 06:01 PMCR- 2022/11/01 CRDT- 2022/12/22 02:18 PHST- 2020/09/03 00:00 [received] PHST- 2021/01/06 00:00 [accepted] PHST- 2022/12/22 02:18 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/23 06:01 [medline] PHST- 2022/11/01 00:00 [pmc-release] AID - atm-10-22-1194 [pii] AID - 10.21037/atm-20-7805 [doi] PST - ppublish SO - Ann Transl Med. 2022 Nov;10(22):1194. doi: 10.21037/atm-20-7805.